Accepted Manuscript

Title: Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?

Author: Milton Packer

PII:	S1071-9164(17)31306-4
DOI:	https://doi.org/10.1016/j.cardfail.2017.12.007
Reference:	YJCAF 4080


To appear in: Journal of Cardiac Failure

 Received date:
 14-11-2017

 Accepted date:
 22-12-2017

Please cite this article as: Milton Packer, Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?, *Journal of Cardiac Failure* (2018), https://doi.org/10.1016/j.cardfail.2017.12.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?

Milton Packer MD

Baylor Heart and Vascular Institute, Baylor University

Medical Center, Dallas, TX, USA

Corresponding Author: Milton Packer, M.D., Baylor Heart and Vascular Institute,

Baylor University Medical Center, 621 N. Hall Street, Dallas TX 75226

Email: milton.packer@baylorhealth.edu

Disclosures: Dr. Packer has recently consulted for Admittance, Amgen, AstraZeneca, Bayer, BioControl, Boehringer Ingelheim, Cardiorentis, CardioKinetix, Celyad, Daiichi Sankyo, Ferring, Gilead, NovoNordisk, Novartis, Relypsa, Sanofi, Takeda and ZS Pharma.

Word count: 957

Download English Version:

https://daneshyari.com/en/article/8667729

Download Persian Version:

https://daneshyari.com/article/8667729

Daneshyari.com